NHNarriane Chaves Pereira de Holanda

Narriane Chaves Pereira de Holanda

*This is an algorithmically generated author record based on publicly available information.

Narriane Chaves Pereira de Holanda has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incretinomiméticos sob olhar bioético: entre terapêutica, estética e justiça sanitária

    by Bruno Leandro de Souza, Caio Chaves de Holanda Limeira, Heloísa Calegari Borges, Narriane Chaves Pereira de Holanda

    Resumo Os incretinomiméticos agonistas do receptor de GLP-1 e agonistas duais GIP/GLP-1 redefiniram o tratamento do diabetes tipo 2 e da obesidade por associarem controle glicêmico, perda ponderal e benefícios cardiovasculares em contextos selecionados. Articulando o principialismo bioético a perspectivas críticas contemporâneas, incluindo bioética de intervenção, justiça sanitária, medicalização e mercantilização do cuidado, esta revisão narrativa sistematizada analisou fundamentos farmacológicos, eficácia, segurança e desafios regulatórios, econômicos e distributivos dessas terapias. Discutem-se as tensões entre uso terapêutico e estético, risco de medicalização do emagrecimento, barreiras de acesso e impactos sobre a sustentabilidade dos sistemas de saúde. Conclui-se que a incorporação eticamente defensável dos incretinomiméticos exige prudência clínica, consentimento esclarecido, acompanhamento longitudinal, critérios transparentes de priorização e compromisso com equidade, continuidade do cuidado e proteção contra desigualdades globais de acesso a inovações farmacológicas.

  • Open Access

    Incretinomiméticos bajo mirada bioética: entre terapéutica, estética y justicia sanitaria

    by Bruno Leandro de Souza, Caio Chaves de Holanda Limeira, Heloísa Calegari Borges, Narriane Chaves Pereira de Holanda

    Resumen Los incretinomiméticos agonistas del receptor de GLP-1 y agonistas duales GIP/GLP-1 han redefinido el tratamiento de la diabetes tipo 2 y la obesidad, asociando control glucémico, pérdida de peso y beneficios cardiovasculares en contextos seleccionados. Esta revisión narrativa sistematizada analizó fundamentos farmacológicos, eficacia, seguridad y desafíos regulatorios, económicos y distributivos de estas terapias, articulando el principialismo bioético con perspectivas críticas contemporáneas, incluyendo bioética de intervención, justicia sanitaria, medicalización y mercantilización del cuidado. Se discuten las tensiones entre uso terapéutico y estético, el riesgo de medicalización del adelgazamiento, las barreras de acceso y los impactos sobre la sostenibilidad de los sistemas de salud. Se concluye que la incorporación éticamente defendible de los incretinomiméticos exige prudencia clínica, consentimiento informado, seguimiento longitudinal, criterios transparentes de priorización y compromiso con equidad, continuidad del cuidado y protección frente a desigualdades globales de acceso a innovaciones farmacológicas.

  • Open Access

    Incretinomimetics under a bioethical lens: between therapeutics, aesthetics and health justice

    by Bruno Leandro de Souza, Caio Chaves de Holanda Limeira, Heloísa Calegari Borges, Narriane Chaves Pereira de Holanda

    GLP-1 receptor agonists and dual GIP/GLP-1 incretinomimetics have redefined the treatment of type 2 diabetes and obesity by combining glycemic control, weight loss, and cardiovascular benefits in selected settings. This systematized narrative review analyzed pharmacological foundations, efficacy, safety, and regulatory, economic, and distributive challenges of these therapies, articulating bioethical principlism with contemporary critical perspectives, including intervention bioethics, health justice, medicalization, and commodification of care. The review discusses tensions between therapeutic and aesthetic use, the risk of medicalizing weight loss, barriers to access, and impacts on health system sustainability. It concludes that the ethically defensible incorporation of incretinomimetics requires clinical prudence, informed consent, longitudinal follow-up, transparent prioritization criteria, and a commitment to equity, continuity of care, and protection against global inequalities in access to pharmacological innovations.

  • Prevalence of Morphometric Vertebral Fractures After Bariatric Surgery and Its Relationship with Bone Mineral Density and Bone Markers

    by Narriane Chaves Pereira de Holanda, Tadeu Iury Araujo Rodrigues Silva, Arthur Gomes Cavalcante, Mariana Braga Lacerda, Gabrielly de Oliveira Viena, Carolina Cabral de Carvalho, Kauê Tavares Menezes, Igor Rosemberg Nóbrega de Medeiros, Marília Moreira Sales, Felipe Reis e Silva de Queiroz, et al.

    Background Bariatric surgery (BS) can lead to bone loss and an increased fracture risk. Methods To determine the morphometric vertebral fracture (MVF) prevalence, and its relationship with bone mineral density (BMD), and biomarker’s turnover after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), we analyzed post-surgery X-rays of the spine in 80 patients (88% female, 51% RYGB, age 41.2 [6.8] years) from 117 participants’ retrospective cohort (1–2 years, >2 and 5 years). We still analyzed body composition and BMD by dual-energy X-ray absorptiometry and bone parameters. Results MVF prevalence was 17.5% (14/80), with no statistical difference between groups (p = 0.210). RYGB group had a higher prevalence of secondary hyperparathyroidism (SHPT) (PTH ≥ 65 pg/ml; 18.4% vs 7.8%, respectively, p = 0.04), PTH (61.3 vs 49.5 pg/ml, p = 0.001), CTX (0.766 [0.29] ng/ml vs 0.453 [0.30] ng/ml, p = 0.037), and AP (101.3 [62.4] U/L vs 123.9 [60.9] U/L, p = 0.027) than the SG group. Up to 5 years postoperatively, RYGB had a lower total (1.200 [0.087] vs 1.236 [0.100] g/cm2, p = 0.02), femoral neck (1.034 [0.110] vs 1.267 [0.105], p = 0.005), and total femur BMD (1.256 [0.155] vs 1.323 [0.167], p = 0.002) than SG group. We found no statistically significant difference between the MFV (+) and MVF (−) groups regarding age, sex, BMI, surgery time, BMD, or bone and metabolic parameters, including leptin. Conclusion We found a high prevalence of MVF after BS with no differences between RYGB and SG. Graphical Abstract


  • Open Access

    Vitamin D Concentration Changes after Bariatric Surgery

    by Vanessa Mayana Alves Baad, Narriane Chaves Pereira de Holanda, Juliana Fonseca Nogueira Alves, Francisco Bandeira, Ana Célia Oliveira dos Santos, Amanda Alves Marcelino da Silva, Taisy Cinthia Ferro Cavalcante

    Introduction. Bariatric surgery causes physiological and anatomical changes in the gastrointestinal tract that interfere with intestinal absorption and, consequently, with the nutritional status, especially about vitamin D. The aim of the study was to evaluate the vitamin D levels and body composition of these patients in the Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) types of surgery. Methods. The retrospective cohort study included a population of 120 patients aged between 18 and 65years, with class II or III obesity, undergoing bariatric surgery procedures (VSG or RYGB-type). Data were collected on the degree of obesity, age, average time since surgery, and gender. The individuals underwent a complete physical examination, measuring blood pressure, weight, height, waist, and neck circumference. In addition to calculating the percentage of loss of body weight and assessing body fat, the food frequency and physical activity of these patients were evaluated. Blood was collected, and the insulin variables, hydroxyvitamin D (25OHD), were analyzed. Results. There was a significant difference between groups only for PTH, total BMD, and insulin variables. A significant intragroup difference was found in the variables body mass index (BMI) and vitamin D for the vertical sleeve gastrectomy group and BMI for the RYGB group. Conclusion. The analysis between the groups of procedures, similarity in body composition and postsurgical vitamin D levels, with significant differences only for PTH, BMD, and insulin variables, demonstrates that both procedures are effective in reducing fat mass.


  • Open Access

    Musculoskeletal effects of obesity and bariatric surgery – a narrative review

    by Narriane Holanda, Nara Crispim, Ingrid Carlos, Taíssa Moura, Eduardo Nóbrega, Francisco Bandeira

    Obesity affects several areas of the human body, leading to increased morbidity and mortality and the likelihood of other diseases, such as type 2 diabetes mellitus, cardiovascular diseases and musculoskeletal disorders. These conditions predispose to bone fractures and sarcopenic obesity, defined by the presence of an obesity-associated decrease in muscle mass and strength. Both bone fragility and sarcopenic obesity disease are consequences of several factors, such as a low degree of chronic inflammation, insulin resistance, hormonal changes, nutritional deficiencies, [...] Abstract Obesity affects several areas of the human body, leading to increased morbidity and mortality and the likelihood of other diseases, such as type 2 diabetes mellitus, cardiovascular diseases and musculoskeletal disorders. These conditions predispose to bone fractures and sarcopenic obesity, defined by the presence of an obesity-associated decrease in muscle mass and strength. Both bone fragility and sarcopenic obesity disease are consequences of several factors, such as a low degree of chronic inflammation, insulin resistance, hormonal changes, nutritional deficiencies,


  • Guia Prático em Osteometabolismo

    by Alexandre Hohl, Amanda Moreira Portes, Ana Carla Montenegro, Ana Oliveira Hoff, Bárbara Campolina C. Silva, Bruno Ferraz de Souza, Carolina Aguiar Moreira, Cynthia M. Álvares Brandão, Dalisbor Marcelo Weber Silva, David William Dempster, et al.

    A relevância e a abordagem consistente dos temas reunidos no Guia Prático em Osteometabolismo asseguraram a publicação dessa nova edição. Preparada pelos membros do Departamento de Metabolismo Ósseo e Mineral da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) e por seus colaboradores, oferece uma visão ainda mais detalhada sobre condições enfrentadas diariamente por clínicos e especialistas, como diabetes mellitus, osteoporose, hipertireoidismo e hipoparatireoidismo. Com isso, o guia mantém a sua condição como material de consulta e referência para profissionais da Endocrinologia e áreas relacionadas.

  • Open Access

    Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO)

    by Barbara C. Silva, Miguel Madeira, Catarina Brasil D’aLva, Sergio Setsuo Maeda, Narriane Chaves Pereira de Holanda, Monique Nakayama Ohe, Vera Szejnfeld, Cristiano A. F. Zerbini, Francisco José Albuquerque de Paula, Francisco Bandeira

    Several drugs are available for the treatment of osteoporosis in postmenopausal women. Over the last decades, most patients requiring pharmacological intervention were offered antiresorptive drugs as first-line therapy, while anabolic agents were considered a last resource for those with therapeutic failure. However, recent randomized trials in patients with severe osteoporosis have shown that anabolic agents reduce fractures to a greater extent than antiresorptive medications. Additionally, evidence indicates that increases in bone mineral density (BMD) are maximized when patients are [...] ABSTRACT Several drugs are available for the treatment of osteoporosis in postmenopausal women. Over the last decades, most patients requiring pharmacological intervention were offered antiresorptive drugs as first-line therapy, while anabolic agents were considered a last resource for those with therapeutic failure. However, recent randomized trials in patients with severe osteoporosis have shown that anabolic agents reduce fractures to a greater extent than antiresorptive medications. Additionally, evidence indicates that increases in bone mineral density (BMD) are maximized when patients are


  • Fracture Risk After Bariatric Surgery: A Systematic Literature Review and Meta-Analysis

    by Narriane Chaves Pereira de Holanda, Ingrid de Lima Carlos, Caio Chaves de Holanda Limeira, David Cesarino de Sousa, Fábio Antônio Serra de Lima Junior, André Telis de Vilela Araújo, Ana Carla Peres Montenegro, Francisco Bandeira


  • Secondary Hyperparathyroidism, Bone Density, and Bone Turnover After Bariatric Surgery: Differences Between Roux-en-Y Gastric Bypass and Sleeve Gastrectomy

    by Narriane Chaves Pereira de Holanda, Vanessa Mayana Alves Baad, Louise Rayra Bezerra, Silvane Katarine Medeiros de Lima, Joao Modesto Filho, Caio Chaves de Holanda Limeira, Taisy Cinthia Ferro Cavalcante, Ana Carla Peres Montenegro, Francisco Bandeira

    Purpose Bariatric surgery may lead to metabolic bone disease. Materials and Methods In this cross-sectional study, we compared the prevalence of secondary hyperparathyroidism (SHPT), impact on bone mass and turnover markers, and serum leptin after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) in 117 patients (91% female, 51% RYGB, age 41.8 ± 6.7 years, time of surgery 4.3 ± 3.4 years) at different times (1–2 years, > 2 and < 5 years and ≥ 5 years). Body composition, bone mineral density (BMD), by dual-energy X-ray absorptiometry, and bone parameters (PTH, serum calcium, 25OHD, alkaline phosphatase (AP), C-telopeptide (CTX)) were analyzed. Results Prevalence of SHPT (PTH ≥ 65 pg/ml) was 26%, RYGB > SG (18.4% vs. 7.8%, p = 0.039), despite similar 25OHD and calcium levels. Mean PTH, CTX, and AP were higher in RYGB vs. SG (61.3 ± 29.5 vs 49.5 ± 32.3 pg/ml, p = 0.001; 0.596 ± 0.24 vs. 0.463 ± 0.23 ng/ml; 123.9 ± 60.8 vs. 100.7 ± 62.0 U/l). There were 13.5% decreases in femoral neck BMD in all patients, over the study period. In the last group, the RYGB group showed greater bone loss in total body BMD (1.016 vs. 1.151 g/cm2, − 8.1%, p = 0.003) and total femur BMD (1.164 vs. 1.267 g/cm2, − 11.7%, p = 0.007). Mean leptin was lower in the RYGB vs. SG group, with no correlation with BMD in any site. Conclusion Our data suggest a more deleterious role of RYGB on bone remodeling up to 5 years postoperatively in comparison with SG. Graphical abstract